Importance of Fibrin Specificity in Therapeutic Thrombolysis and the Rationale of Using Sequential and Synergistic Combinations of Tissue Plasminogen Activator and Pro-Urokinase

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  1989-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-2007-1002694PMID 2501871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.

  1988cited by this paper
• Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

  1988cited by this paper
• CLINICAL RESEARCH ON SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (SCU-PA) IN GERMANY. RESULTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)

  1987cited by this paper
• Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.

  1987cited by this paper
• Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase).

  1987cited by this paper
• Synergism of Tissue-Type Plasminogen Astivator (t-PA) and Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) on Clot Lysis In Vitro and a Mechanism for this Effect

  1987cited by this paper
• Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.

  1987cited by this paper
• Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction?

  1987cited by this paper
• Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.

  1987cited by this paper
• Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit.

  1987cited by this paper
• SENSITIVE AND QUANTITATIVE ASSAYS OF FUNCTIONALLY ACTIVE PLASMINOGEN ACTIVATORS IN PLASMA

  1987cited by this paper
• Activation of the complement system by recombinant tissue plasminogen activator.

  1987cited by this paper
• Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.

  1986cited by this paper
• Activation of plasminogen by pro-urokinase. I. Mechanism.

  1986cited by this paper
• Synergism of thrombolytic agents in vivo.

  1986cited by this paper
• Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.

  1986cited by this paper
• A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.

  1986cited by this paper
• Thrombolysis. Biological and Therapeutic Properties of New Thrombolytic Agents

  1986cited by this paper
• Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.

  1986cited by this paper
• The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

  1985cited by this paper
• Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions.

  1985cited by this paper
• Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor.

  1984cited by this paper
• Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator.

  1983cited by this paper
• Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator.

  1982cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

  1981cited by this paper
• Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor

  1981cited by this paper
• Purification Of A New High Mw Single Chain Form Of Urokinase (UK) From Urine

  1981cited by this paper
• Concentration of plasminogen and antiplasmin in plasma and serum

  1981cited by this paper
• Molecular mechanism of physiological fibrinolysis

  1978cited by this paper
• Synergy, additivism and antagonism in immunosuppression. A critical review.

  1977cited by this paper
• Excercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates.

  1974cited by this paper
• Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis.

  1973cited by this paper
• THE CONVERSION OF C'1S TO C'1 ESTERASE BY PLASMIN AND TRYPSIN

  1967cited by this paper
• A PLASMIN-SPLIT FRAGMENT OF C'3 AS A NEW CHEMOTACTIC FACTOR

  1967cited by this paper

• [Clinical significance of the fibrinolysis system].

  2008cites this paper
• Potentiation and acceleration effects in combined administration of tissue plasminogen activator and fibrinogen-modified urokinase in dogs with modeled venous thrombosis

  2006cites this paper
• Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase)

  2001cites this paper
• STRUCTURE - FUNCTION STUDIES OF PLASMINOGEN ACTIVATOR INHIBITOR-1

  1998cites this paper
• Effective Enzyme Thrombolytic Composition on the Basis of Wild‐type and Chemically Modified Plasminogen Activators a

  1996cites this paper
• Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate

  1996cites this paper
• Thromboelastographic Study of Fibrinolytic Agents

  1995cites this paper
• Differences in u-PA and t-PA increase during acute exercise: relation with exercise parameters.

  1994cites this paper
• Experimental combined thrombolytic therapy: The current position and directions of progress (review)

  1994cites this paper
• Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.

  1993cites this paper
• Pro to gly (p219g) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator

  1993cites this paper
• Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen.

  1992cites this paper
• Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II.

  1991cites this paper
• Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-tPA derivative.

  1991cites this paper
• Fibrinolytic Therapy: Biochemical Mechanisms

  1991cites this paper
• Physical Exercise Induces Enhancement of Urokinase-Type Plasminogen Activator (u-PA) Levels in Plasma

  1991cites this paper